According to a Federal Trade Commission lawsuit filed in California, beginning in or around March 2020, Marc Ching of Whole Leaf Organics began marketing Thrive as an “anti viral wellness booster” that treats, prevents or reduces the risk of COVID...
A recent batch of warning letters from the Federal Trade Commission, attorney Kevin Thompson said, send a clear message that multi-level marketers should not "commingle any product promotion or income opportunity with COVID."
Some of the nation’s largest and most prominent marketers of CBD have raised various defenses in response to a wave of lawsuits filed in late 2019 against them.
CBD thrives despite unresolved or emerging legal issues, meaning companies involved with cannabinoids had better assess their current and future legal exposure.
A contract manufacturer of dietary supplements for years fell short of regulations intended to ensure products are safe and made to quality standards.
Marketers of CBD ensnared in class action litigation could get some temporary relief if courts invoke a doctrine known as “primary jurisdiction."
FDA has increasingly relied on the Park Doctrine—which states that the government can convict a company executive even if he isn’t aware of a violation of the FD&C—to act against supplement brands.
The Supreme Court on Monday denied Amarin Pharma Inc.’s petition for a writ of certiorari in a case over the legality of certain "synthetically produced omega-3 products" promoted as dietary supplements.
FDA’s batch of warning letters last month to CBD marketers spawned a growing number of proposed class action lawsuits.
The Center for Science in the Public Interest (CSPI) reported its investigation of 39 fertility supplements found no evidence that they help women become pregnant and are being marketed as unapproved new drugs.